Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- URGN
- Price
- 14.65
- Stock movement up
- +0.47 (2.43%)
- Company name
- UroGen Pharma Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 915.10M
- Ent value
- 1.07B
- Price/Sales
- 10.24
- Price/Book
- 35.87
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -5.89%
- 1 year return
- 34.38%
- 3 year return
- 32.93%
- 5 year return
- -2.93%
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
URGN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10.24 |
| Price to Book | 35.87 |
| EV to Sales | 11.94 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 46.26M |
| EPS (TTM) | -2.68 |
| FCF per share (TTM) | -2.24 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 89.36M |
| Gross profit (TTM) | 80.67M |
| Operating income (TTM) | -83.73M |
| Net income (TTM) | -115.38M |
| EPS (TTM) | -2.68 |
| EPS (1y forward) | -1.63 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 90.27% |
| Operating margin (TTM) | -93.70% |
| Profit margin (TTM) | -129.11% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 124.92M |
| Net receivables | 22.80M |
| Total current assets | 295.10M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 5.87M |
| Total assets | 301.94M |
| Accounts payable | 5.56M |
| Short/Current long term debt | 121.92M |
| Total current liabilities | 32.79M |
| Total liabilities | 276.43M |
| Shareholder's equity | 25.52M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -96.20M |
| Capital expenditures (TTM) | 233.54K |
| Free cash flow (TTM) | -96.44M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -452.20% |
| Return on Assets | -38.21% |
| Return on Invested Capital | -77.93% |
| Cash Return on Invested Capital | -65.14% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 19.31 |
| Daily high | 20.11 |
| Daily low | 19.11 |
| Daily Volume | 730K |
| All-time high | 65.33 |
| 1y analyst estimate | 32.00 |
| Beta | 1.13 |
| EPS (TTM) | -2.68 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Nov 2025 |
Downside potential
Loading...
Downside potential data
| URGN | S&P500 | |
| Current price drop from All-time high | -69.72% | -1.46% |
| Highest price drop | -93.98% | -56.47% |
| Date of highest drop | 27 May 2025 | 9 Mar 2009 |
| Avg drop from high | -60.98% | -10.99% |
| Avg time to new high | 49 days | 12 days |
| Max time to new high | 1825 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
915.10M
Marketcap category
Small-cap
Description
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Employees
253
Website
Investor relations
-
SEC filings
CEO
Elizabeth Barrett
Country
USA
City
Princeton
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page